TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30256303

Group type: EXPERIMENTAL
Intervention: Dorsal harness attachment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frontal harness attachment
Number of subjects: 0
Study: 29097450

Group type: EXPERIMENTAL
Intervention: PCI plus MT
Number of subjects: 888

Group type: COMPARATOR
Intervention: MT alone
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: PCI compared with MT
Number of subjects: 888
Study: 27217544

Group type: EXPERIMENTAL
Intervention: >5% weight gain
Number of subjects: 2301
Study: 24650024

Group type: EXPERIMENTAL
Intervention: ABG‐I anatomical stem
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unique femoral stem
Number of subjects: 100
Study: 22201324

Group type: EXPERIMENTAL
Intervention: Optimized prolate ablation (OPA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Optimized aspheric treatment zone ablation (OATz)
Number of subjects: 40
Study: 20398349

Group type: EXPERIMENTAL
Intervention: Supervised general exercise programme
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Individualized walking programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 60
Study: 17976843

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with and without defibrillator back‐up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subgroup analyses of prospective randomized ICD‐ and CRT‐intervention trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Published cohort studies
Number of subjects: 0
Study: 16448994

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: CABG within the first 30 days
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: CABG after 30 days
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: CABG within the first year after STEMI
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Early CABG
Number of subjects: 131
Study: 12008991

Group type: EXPERIMENTAL
Intervention: Treatment group (n=54) attended two group nutrition education classes and one individual diet counseling session led by the same dietitian.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (n=50) received usual nonindividualized nutrition education from cardiac rehabilitation therapists.
Number of subjects: 104
Study: 10321414

Group type: EXPERIMENTAL
Intervention: Eprosartan 600 mg once daily
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 8735463

Group type: EXPERIMENTAL
Intervention: Dermal exposure to 86 mg/m3 cis-1,3-DCP for 45 minutes
Number of subjects: 5
Study: 1767904

Group type: EXPERIMENTAL
Intervention: Midazolam IV solution 10 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 6412612

Group type: EXPERIMENTAL
Intervention: alfentanil 0.75 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: fentanyl 0.25 mg
Number of subjects: 66
Study: 29545067

Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg intravenous every 4 weeks for 2 years
Number of subjects: 889

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Natalizumab (continuing patients)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Natalizumab (naive patients)
Number of subjects: 889
Study: 27253526

Group type: EXPERIMENTAL
Intervention: Vegan diet (excluding animal-based food including fish)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional diabetic diet recommended by the Korean Diabetes Association 2011
Number of subjects: 93
Study: 25712913

Group type: EXPERIMENTAL
Intervention: Integrating Homologous Samples (IHS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomly Dividing Homologous Samples (RDHS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrating Homologous Samples (IHS) with feature selection
Number of subjects: 0
Study: 23203322

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA, 10 mg/d for 10 days per cycle)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Norethisterone (NET, 15 mg/d for 10 days per cycle)
Number of subjects: 90
Study: 20194584

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 19008622

Group type: EXPERIMENTAL
Intervention: Acidic center-filled chewing gum (pure, 4X/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acidic center-filled chewing gum (diluted, 4X/day)
Number of subjects: 80
Study: 16469126

Group type: EXPERIMENTAL
Intervention: Computerized unit (C-U)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Paper-based unit (PB-U)
Number of subjects: 160
Study: 14623537

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg)
Number of subjects: 9366

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg)
Number of subjects: 9366

Group type: COMPARATOR
Intervention: Combination treatment (anastrozole + tamoxifen)
Number of subjects: 9366
Study: 10928757

Group type: EXPERIMENTAL
Intervention: Ofloxacin drops (one drop every night for one week, then one drop once a week for one month)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bacitracin ointment (or erythromycin/gentamicin if resistant to bacitracin) applied to the lid margin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (15 volunteers, 30 lids)
Number of subjects: 19
Study: 8922762

Group type: EXPERIMENTAL
Intervention: Humidified isoflurane
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-humidified isoflurane
Number of subjects: 59
Study: 1279571

Group type: COMPARATOR
Intervention: DDD pacing mode
Number of subjects: 16

Group type: COMPARATOR
Intervention: VVIR pacing mode
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DDDR pacing mode
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DDDR pacing mode in patients with isolated sinus node disease (n = 9)
Number of subjects: 16

Group type: COMPARATOR
Intervention: DDDR pacing mode in patients with intermittent second or third degree AV block (n = 7)
Number of subjects: 16
Study: 3894250

Group type: EXPERIMENTAL
Intervention: Acebutolol (100 mg intravenous perfusion over 24 hr or 600 mg orally, followed by 1200 mg/day orally)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (no acebutolol)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Acebutolol and Control
Number of subjects: 71
Study: 29148629

Group type: EXPERIMENTAL
Intervention: Mouth rinse with carbohydrate solution (MRCS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no mouth rinse)
Number of subjects: 21
Study: 30227642

Group type: EXPERIMENTAL
Intervention: Game-Based Learning (GBL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gamification
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (Traditional Teaching Method)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall (GBL and Gamification vs Control)
Number of subjects: 120
Study: 25545313

Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone (DBB) graft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no graft)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups over time
Number of subjects: 20
Study: 25500201

Group type: EXPERIMENTAL
Intervention: School-based prevention program 'Paesaggi di Prevenzione'
Number of subjects: 7652
Study: 22622138

Group type: EXPERIMENTAL
Intervention: Baseline PIIINP levels <0.72 U/mL
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Baseline PIIINP levels >0.72 U/mL
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Baseline PIIINP
Number of subjects: 142
Study: 20860916

Group type: EXPERIMENTAL
Intervention: Test formulation of mycophenolate mofetil 500 mg (Suprimun®)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of mycophenolate mofetil 500 mg
Number of subjects: 24
Study: 19094408

Group type: EXPERIMENTAL
Intervention: Training designed to improve information management knowledge, skills, and use of Web-based resources.
Number of subjects: 0
Study: 16687365

Group type: EXPERIMENTAL
Intervention: Mecamylamine (6 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 11814370

Group type: EXPERIMENTAL
Intervention: Health Buddy interactive device
Number of subjects: 134

Group type: COMPARATOR
Intervention: Asthma diary
Number of subjects: 134
Study: 10417456

Group type: EXPERIMENTAL
Intervention: Neostigmine 20 microgram.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neostigmine 35 microgram.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neostigmine 50 microgram.kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neostigmine (35 or 50 microgram.kg‐1) with isoflurane discontinued
Number of subjects: 120

Group type: COMPARATOR
Intervention: Atropine instead of glycopyrronium with neostigmine
Number of subjects: 120
Study: 8770800

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) leg cycle ergometry training, 30-minute sessions, total of 24 sessions over 19 weeks.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Submaximal NMES leg cycle exercise at an absolute work rate (0 W).
Number of subjects: 8
Study: 2019078

Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Normal exercise activities (lifters)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Injury (runner)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control week (non-active subjects and runners)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Weight training
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Muscular injury
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intense weight-lifting session
Number of subjects: 7
Study: 417671

Group type: EXPERIMENTAL
Intervention: Ticarcillin (T)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Carbenicillin (C)
Number of subjects: 253
Study: 31597536

Group type: EXPERIMENTAL
Intervention: theory-based, data-driven, multimedia, simulated concussion reporting module
Number of subjects: 520

Group type: COMPARATOR
Intervention: NCAA Concussion Fact Sheet
Number of subjects: 520
Study: 31037806

Group type: EXPERIMENTAL
Intervention: Low-volume resistance training (6 months, twice a week)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (maintained pharmacological treatments)
Number of subjects: 54
Study: 28363197

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Short message service (SMS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 25514098

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous Moderate-Intensity Exercise (CME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 0
Study: 23421600

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 3 g/day with riluzole 100 mg/day
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo 3 g/day with riluzole 100 mg/day
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 16480789

Group type: EXPERIMENTAL
Intervention: Dual-task training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 14732410

Group type: EXPERIMENTAL
Intervention: Imagined self-rotations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagined self-translations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advance information about the to-be-imagined perspective
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both tasks (self-rotations and self-translations)
Number of subjects: 0
Study: 10980908

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary prevention strategies and risk factor modification
Number of subjects: 0
Study: 9098093

Group type: EXPERIMENTAL
Intervention: Oil-based Q10 (90 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Granular Q10 (90 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (Oil-based, Granular, Placebo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oil-based and Granular Q10
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 mg Q10 (single dose)
Number of subjects: 60
Study: 8218955

Group type: EXPERIMENTAL
Intervention: Transnasal administration of butorphanol (2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual administration of butorphanol (2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buccal administration of butorphanol (2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration of butorphanol (2 mg)
Number of subjects: 0
Study: 3700691

Group type: EXPERIMENTAL
Intervention: Cimetidine 1,200 mg/d
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg/d
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30537626

Group type: EXPERIMENTAL
Intervention: Sticky mittens training (4-minute session with Velcro covered toys)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study: 28743757

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agent (ESA) treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Baseline measurement
Number of subjects: 29
Study: 26914029

Group type: EXPERIMENTAL
Intervention: HCV nosode at 30C and 50C potencies
Number of subjects: 24
Study: 25112372

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 57
Study: 22269382

Group type: EXPERIMENTAL
Intervention: Screening arm (PSA every 4 years, prostate biopsy when PSA ≥3 ng/ml)
Number of subjects: 4278

Group type: COMPARATOR
Intervention: Control arm (no tests)
Number of subjects: 4278
Study: 19738493

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 74
Study: 17513813

Group type: EXPERIMENTAL
Intervention: Active specific immunotherapy with allogeneic melanoma lysates and low-dose interferon alfa-2b (IFN-alpha-2b) for 2 years
Number of subjects: 604

Group type: COMPARATOR
Intervention: High-dose interferon alfa-2b for 1 year
Number of subjects: 604
Study: 14966348

Group type: EXPERIMENTAL
Intervention: 3 Gy fractions (group A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 5 Gy fractions (group B)
Number of subjects: 46
Study: 12243812

Group type: EXPERIMENTAL
Intervention: Postoperative radiation with concomitant and maintenance chemotherapy (96% of patients)
Number of subjects: 2551
Study: 9659245

Group type: EXPERIMENTAL
Intervention: Throat swabs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sputum specimens
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both specimens (throat swab and sputum)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Overall detection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paired specimens
Number of subjects: 50
Study: 8586126

Group type: EXPERIMENTAL
Intervention: OKY-046 (400 mg/day)
Number of subjects: 0
Study: 2765345

Group type: EXPERIMENTAL
Intervention: Priming with alcuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming with tubocurarine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no priming)
Number of subjects: 0
Study: 823084

Group type: EXPERIMENTAL
Intervention: Butalamine hydrochloride (3 X 2 tablets daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31462137

Group type: EXPERIMENTAL
Intervention: NLR ≥ 5
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Adding NLR to MSKCC variables
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Adding NLR among patients who died before 24 months (N=415)
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Adding NLR among those alive at 24 months (N=636)
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: NLR with IMDC variables
Number of subjects: 1102
Study: 30600173

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 76
Study: 28335837

Group type: EXPERIMENTAL
Intervention: Potent P2Y12 inhibitors (prasugrel, ticagrelor, intravenous cangrelor)
Number of subjects: 87640

Group type: EXPERIMENTAL
Intervention: Potent P2Y12 inhibitors
Number of subjects: 87640
Study: 24799153

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 23865839

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 21893645

Group type: EXPERIMENTAL
Intervention: Maternal kangaroo care (KC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Paternal kangaroo care (KC)
Number of subjects: 62
Study: 19744976

Group type: EXPERIMENTAL
Intervention: Qualitative studies conducted alongside randomised controlled trials
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Qualitative studies conducted before the trial
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Qualitative studies conducted during the trial
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Qualitative studies conducted after the trial
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Integration of qualitative and quantitative findings
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quality of qualitative studies
Number of subjects: 100
Study: 17102667

Group type: EXPERIMENTAL
Intervention: First eye surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Second eye surgery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laser ablation for both eyes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative period for both eyes
Number of subjects: 50
Study: 15143715

Group type: EXPERIMENTAL
Intervention: Yinchenghao decoction (YCHD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: S-adenosy-L-methionine (SAM)
Number of subjects: 60
Study: 11371893

Group type: EXPERIMENTAL
Intervention: Immediate cystoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed cystoscopy
Number of subjects: 100
Study: 9209184

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (0.75 L carbohydrate beverage, 0.25 L every 15 min during running)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0.75 L placebo beverage, 0.25 L every 15 min during running)
Number of subjects: 30
Study: 8094467

Group type: EXPERIMENTAL
Intervention: Taxol (250 mg/m2 by 24-hour intravenous infusion every 3 weeks)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Merbarone (1000 mg/m2 by continuous intravenous infusion daily for 5 days every 3 weeks)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Piroxantrone (150 mg/m2 by intravenous infusion over 1 hour every 3 weeks)
Number of subjects: 119
Study: 2887097

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Combination of Nifedipine and Metoprolol
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Nifedipine (in patients already receiving beta blockers)
Number of subjects: 338
Study: 31620860

Group type: EXPERIMENTAL
Intervention: Kinesiology taping (KT) 50% stretch
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Kinesiology taping (KT) 80% stretch
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal swallowing (without KT)
Number of subjects: 23
Study: 29504207

Group type: EXPERIMENTAL
Intervention: HIT-enhanced SMBG
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Family-centered goal setting
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Combined approach (HIT-enhanced SMBG + family-centered goal setting)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Combined approach vs HIT-enhanced SMBG
Number of subjects: 128

Group type: COMPARATOR
Intervention: Combined approach vs Family-centered goal setting
Number of subjects: 128
Study: 27333620

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone combined with rhTPO
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single high-dose dexamethasone
Number of subjects: 48
Study: 25192026

Group type: EXPERIMENTAL
Intervention: 10 mg Zn/day (experimental group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study: 21283046

Group type: EXPERIMENTAL
Intervention: Interrupted sedation protocol (midazolam bolus of 0.1 mg/kg, followed by infusion with daily interruption)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Continuous sedation protocol (midazolam bolus of 0.1 mg/kg, followed by continuous infusion)
Number of subjects: 102
Study: 20354006

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% infiltration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infiltration (control)
Number of subjects: 12
Study: 18764823

Group type: EXPERIMENTAL
Intervention: Washed blood (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unwashed blood (Group B)
Number of subjects: 0
Study: 15972728

Group type: EXPERIMENTAL
Intervention: Trimethoprim 300 mg daily for three days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 59
Study: 12579169

Group type: EXPERIMENTAL
Intervention: Timolol/dorzolamide fixed combination
Number of subjects: 65

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 65
Study: 11116505

Group type: EXPERIMENTAL
Intervention: Central corneal thickness measurement
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Correction factor for corneal thickness
Number of subjects: 98